IMUGENE LIMITED - Announcements

Market Cap $548.9M Add to my watchlist

Healthcare Biotechnology

Imugene Limited is a clinical-stage immune-oncology company. It is engaged in developing... Imugene Limited is a clinical-stage immune-oncology company. It is engaged in developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its platform technology seeks to harness and promote the body’s immune system against cancerous tumors. Its product pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug Azer-Cel (azercabtagene zapreleucel) which targets CD19 to attack blood cancer. Its pipeline includes an Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard of care drugs and immunotherapies. Its lead candidate is a chimeric vaccinia (pox) virus known as CF33, which is a combination of genomic sequences from multiple vaccinia virus strains to generate a new, safer and more potent virus. Its Chimeric antigen receptor (CAR)-engineered T cells (CAR T) are T cells redirected against tumors through engineered expression of CARs. More

Human-Like Digital Interactions

Unith (ASX:UNT) is an integrated AI company that develop digital avatars that converse in real-time with any audience, making user-centric communication more scalable for businesses. NEWS: UNITH shares jump 7% as ex-Microsoft VP for Asia joins board.

Announcements

Filter Results

All Price Sensitive Only

IMU	Final Director's Interest Notice		07/07/23	7.43KB	Share
IMU	New Dose Escalation in Phase I Clinical Trial of CHECKvacc	PRICE SENSITIVE	07/07/23	135.06KB	Share
IMU	Letter to Shareholders		06/07/23	212.92KB	Share
IMU	Change of Director's Interest Notice		30/06/23	20.97KB	Share
IMU	HER-Vaxx induced antibodies correlated with tumour reduction	PRICE SENSITIVE	30/06/23	145.8KB	Share
IMU	Imugene PD1-Vaxx patent extended to 2040	PRICE SENSITIVE	29/06/23	119.39KB	Share
IMU	Initial Director's Interest Notice		23/06/23	141.06KB	Share
IMU	Imugene Appoints Kim Drapkin as Non-Executive Director		21/06/23	127.89KB	Share
IMU	Imugene Advances VAXINIA MAST Trial to Next IV Cohorts	PRICE SENSITIVE	09/06/23	164.13KB	Share
IMU	Imugene doses first combination patient in PD1-Vaxx trial	PRICE SENSITIVE	01/06/23	150.45KB	Share
IMU	Imugene Investor Webinar - FDA IND Clearance for onCARlytics		19/05/23	123.53KB	Share
IMU	FDA clears Imugene IND for onCARlytics first-in-class study	PRICE SENSITIVE	19/05/23	285.34KB	Share
IMU	onCARlytics with ARTEMIS T cells show anti-tumour activity	PRICE SENSITIVE	18/05/23	135.87KB	Share
IMU	onCARlytics with Artemis T cells abstract presented at ASGCT	PRICE SENSITIVE	03/05/23	127.55KB	Share
IMU	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/04/23	1.33MB	Share
IMU	Imugene receives $12.6m R&D tax refund	PRICE SENSITIVE	26/04/23	131.8KB	Share
IMU	Imugene Images and Follows CHECKVacc in TNBC Patients	PRICE SENSITIVE	20/04/23	151.57KB	Share
IMU	First patients dosed in IT & IV cohort 3 of VAXINIA trial	PRICE SENSITIVE	05/04/23	499.46KB	Share
IMU	Imugene Presentation to NWR Healthcare Conference		22/03/23	5.9MB	Share
IMU	Imugene to present at NWR Virtual Healthcare Conference		16/03/23	109.95KB	Share
IMU	Imugene Corporate Presentation		15/03/23	6.05MB	Share
IMU	Notice Under Section 708A		10/03/23	104.33KB	Share
IMU	Notification regarding unquoted securities - IMU		10/03/23	33.79KB	Share
IMU	Application for quotation of securities - IMU		10/03/23	34.71KB	Share
IMU	Change of Registered Office		08/03/23	121.45KB	Share
IMU	First Patients Dosed in Combination Study of VAXINIA	PRICE SENSITIVE	03/03/23	195.69KB	Share
IMU	Imugene appoints CFO Mike Tonroe as Company Secretary		02/03/23	127.46KB	Share
IMU	Half Yearly Report and Accounts	PRICE SENSITIVE	28/02/23	1.12MB	Share
IMU	Application for quotation of securities - IMU		22/02/23	26.5KB	Share
IMU	Imugene PD1-Vaxx Immunotherapy Patent Granted in the US	PRICE SENSITIVE	10/02/23	126.56KB	Share
IMU	Imugene VAXINIA trial advances to Combination Cohort	PRICE SENSITIVE	02/02/23	194.71KB	Share
IMU	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	27/01/23	458.7KB	Share
IMU	HER-Vaxx and CF33 Platforms Featured at ASCO Symposium		20/01/23	177.93KB	Share
IMU	Imugene Presentation to the JP Morgan Healthcare Conference		09/01/23	4.49MB	Share
IMU	Imugene Receives Vaxinia Ethics Approval in Australia	PRICE SENSITIVE	09/01/23	202.94KB	Share
IMU	Letter to Shareholders		06/01/23	174.3KB	Share
IMU	Notification regarding unquoted securities - IMU		22/12/22	34.22KB	Share
IMU	Notification regarding unquoted securities - IMU		22/12/22	25.8KB	Share
IMU	Ceasing to be a substantial holder		22/12/22	78.5KB	Share
IMU	Ceasing to be a substantial holder		20/12/22	200.27KB	Share
IMU	Change of Director's Interest Notice x6		20/12/22	356.36KB	Share
IMU	Notification of cessation of securities - IMU		16/12/22	21.74KB	Share
IMU	Notification regarding unquoted securities - IMU		16/12/22	40.1KB	Share
IMU	Imugene HER-Vaxx and CF33 Platforms To Feature at ASCO		16/12/22	365.28KB	Share
IMU	Imugene to Present at J.P. Morgan Healthcare Conference		12/12/22	139.32KB	Share
IMU	CHECKVacc Data Presented at the 2022 SABC Symposium	PRICE SENSITIVE	09/12/22	252.41KB	Share
IMU	Appendix 3H		06/12/22	222.27KB	Share
IMU	Notice Under Section 708A		05/12/22	156.77KB	Share
IMU	Appendix 2A		05/12/22	383.23KB	Share
IMU	First Patient Dosed in VAXINIA Intravenous Cohort 2	PRICE SENSITIVE	05/12/22	250.44KB	Share
IMU	Positive New HER-Vaxx HERIZON Data Presented at ESMO Asia	PRICE SENSITIVE	05/12/22	209.85KB	Share
IMU	Application for quotation of securities - IMU		25/11/22	25.74KB	Share
IMU	Application for quotation of securities - IMU		18/11/22	25.67KB	Share
IMU	Results of Meeting		17/11/22	161.97KB	Share
IMU	AGM Presentation		17/11/22	2.98MB	Share
IMU	Imugene Investor Presentation		15/11/22	4.19MB	Share
IMU	Imugene onCARlytics with Estrella ARTEMIS T Cells SITC	PRICE SENSITIVE	14/11/22	255.3KB	Share
IMU	Application for quotation of securities - IMU		11/11/22	25.67KB	Share
IMU	Dose escalates In Phase I Clinical Trial of New Oncolytic Vi	PRICE SENSITIVE	11/11/22	250.51KB	Share
IMU	Imugene onCARlytics with blinatumomab SITC presentation	PRICE SENSITIVE	11/11/22	244.77KB	Share
IMU	Imugene onCARlytics with Celularity CyCART-19 T Cells SITC	PRICE SENSITIVE	11/11/22	306.65KB	Share
IMU	Change of Director's Interest Notice - JE & CW		09/11/22	377.77KB	Share
IMU	AGM ATTENDANCE		08/11/22	162.86KB	Share
IMU	ALA: Europe Patent granted for iNKT Cell Therapy Platform	PRICE SENSITIVE	07/11/22	150.42KB	Share
IMU	Notice Under Section 708A		03/11/22	158.21KB	Share
IMU	Application for quotation of securities - IMU		03/11/22	37.66KB	Share
IMU	First patient dosed in VAXINIA intratumoral cohort 2	PRICE SENSITIVE	31/10/22	228.66KB	Share
IMU	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/10/22	608KB	Share
IMU	Application for quotation of securities - IMU		27/10/22	26.55KB	Share
IMU	Application for quotation of securities - IMU		21/10/22	26.54KB	Share
IMU	Letter to IMUOC Optionholders		19/10/22	1022.25KB	Share
IMU	Release of Shares from Escrow		19/10/22	130.31KB	Share
IMU	ABL and Imugene partner to advance VAXINIA manufacturing		18/10/22	201.66KB	Share
IMU	Notice of Annual General Meeting/Proxy Form		14/10/22	1.42MB	Share
IMU	Application for quotation of securities - IMU		13/10/22	26.55KB	Share
IMU	HERIZON study results to be featured at ESMO Asia Congress		07/10/22	188.8KB	Share
IMU	onCARlytics to be showcased in three abstracts at SITC		06/10/22	211.96KB	Share
IMU	Imugene appoints Paul Wright as Vice President CMC		04/10/22	188.43KB	Share
IMU	Imugene appoints Dr Giovanni Selvaggi as CMO		04/10/22	189.81KB	Share
IMU	ALA iNKT therapy and IMU onCARlytics - correction		27/09/22	223.26KB	Share
IMU	ALA: Investor Presentation Imugene Arovella Therapies		26/09/22	4.83MB	Share
IMU	Preclinical trial of ALA iNKT therapy and IMU onCARlytics	PRICE SENSITIVE	26/09/22	219.23KB	Share
IMU	First patient IV dosed in VAXINIA Phase 1 clinical trial	PRICE SENSITIVE	21/09/22	189.98KB	Share
IMU	Notification regarding unquoted securities - IMU		20/09/22	30.21KB	Share
IMU	Notice Under Section 708A		19/09/22	152.38KB	Share
IMU	Application for quotation of securities - IMU		19/09/22	26.56KB	Share
IMU	OGTR grants VAXINIA DIR licence allowing trial expansion	PRICE SENSITIVE	19/09/22	212.02KB	Share
IMU	Prospectus for the issue of institutional placement options	PRICE SENSITIVE	16/09/22	604.08KB	Share
IMU	Proposed issue of securities - IMU		13/09/22	28.88KB	Share
IMU	IMUGENE ANNOUNCES A$80 MILLION INSTITUTIONAL PLACEMENT	PRICE SENSITIVE	13/09/22	361.45KB	Share
IMU	Trading Halt	PRICE SENSITIVE	12/09/22	220.02KB	Share
IMU	Imugene doses first patient in nextHERIZON Phase 2 trial	PRICE SENSITIVE	08/09/22	191.8KB	Share
IMU	Application for quotation of securities - IMU		07/09/22	26.5KB	Share
IMU	Initial Director's Interest Notice - JD		07/09/22	161.02KB	Share
IMU	Imugene appoints Dr Jakob Dupont as Non-Executive Director		07/09/22	188.56KB	Share
IMU	Application for quotation of securities - IMU		02/09/22	29.16KB	Share
IMU	Release of Shares from Escrow		01/09/22	130.41KB	Share
IMU	Imugene Dose Escalates in Phase I Clinical Trial of VAXINIA	PRICE SENSITIVE	01/09/22	232.91KB	Share
IMU	Environmental Social and Governance (ESG) Report		31/08/22	496.25KB	Share
IMU	Corporate Governance Statement		31/08/22	203.19KB	Share

IMU Final Director's Interest Notice
07/07/23		7.43KB	Share
IMU New Dose Escalation in Phase I Clinical Trial of CHECKvacc
07/07/23	PRICE SENSITIVE	135.06KB	Share
IMU Letter to Shareholders
06/07/23		212.92KB	Share
IMU Change of Director's Interest Notice
30/06/23		20.97KB	Share
IMU HER-Vaxx induced antibodies correlated with tumour reduction
30/06/23	PRICE SENSITIVE	145.8KB	Share
IMU Imugene PD1-Vaxx patent extended to 2040
29/06/23	PRICE SENSITIVE	119.39KB	Share
IMU Initial Director's Interest Notice
23/06/23		141.06KB	Share
IMU Imugene Appoints Kim Drapkin as Non-Executive Director
21/06/23		127.89KB	Share
IMU Imugene Advances VAXINIA MAST Trial to Next IV Cohorts
09/06/23	PRICE SENSITIVE	164.13KB	Share
IMU Imugene doses first combination patient in PD1-Vaxx trial
01/06/23	PRICE SENSITIVE	150.45KB	Share
IMU Imugene Investor Webinar - FDA IND Clearance for onCARlytics
19/05/23		123.53KB	Share
IMU FDA clears Imugene IND for onCARlytics first-in-class study
19/05/23	PRICE SENSITIVE	285.34KB	Share
IMU onCARlytics with ARTEMIS T cells show anti-tumour activity
18/05/23	PRICE SENSITIVE	135.87KB	Share
IMU onCARlytics with Artemis T cells abstract presented at ASGCT
03/05/23	PRICE SENSITIVE	127.55KB	Share
IMU Quarterly Activities/Appendix 4C Cash Flow Report
28/04/23	PRICE SENSITIVE	1.33MB	Share
IMU Imugene receives $12.6m R&D tax refund
26/04/23	PRICE SENSITIVE	131.8KB	Share
IMU Imugene Images and Follows CHECKVacc in TNBC Patients
20/04/23	PRICE SENSITIVE	151.57KB	Share
IMU First patients dosed in IT & IV cohort 3 of VAXINIA trial
05/04/23	PRICE SENSITIVE	499.46KB	Share
IMU Imugene Presentation to NWR Healthcare Conference
22/03/23		5.9MB	Share
IMU Imugene to present at NWR Virtual Healthcare Conference
16/03/23		109.95KB	Share
IMU Imugene Corporate Presentation
15/03/23		6.05MB	Share
IMU Notice Under Section 708A
10/03/23		104.33KB	Share
IMU Notification regarding unquoted securities - IMU
10/03/23		33.79KB	Share
IMU Application for quotation of securities - IMU
10/03/23		34.71KB	Share
IMU Change of Registered Office
08/03/23		121.45KB	Share
IMU First Patients Dosed in Combination Study of VAXINIA
03/03/23	PRICE SENSITIVE	195.69KB	Share
IMU Imugene appoints CFO Mike Tonroe as Company Secretary
02/03/23		127.46KB	Share
IMU Half Yearly Report and Accounts
28/02/23	PRICE SENSITIVE	1.12MB	Share
IMU Application for quotation of securities - IMU
22/02/23		26.5KB	Share
IMU Imugene PD1-Vaxx Immunotherapy Patent Granted in the US
10/02/23	PRICE SENSITIVE	126.56KB	Share
IMU Imugene VAXINIA trial advances to Combination Cohort
02/02/23	PRICE SENSITIVE	194.71KB	Share
IMU Quarterly Activities/Appendix 4C Cash Flow Report
27/01/23	PRICE SENSITIVE	458.7KB	Share
IMU HER-Vaxx and CF33 Platforms Featured at ASCO Symposium
20/01/23		177.93KB	Share
IMU Imugene Presentation to the JP Morgan Healthcare Conference
09/01/23		4.49MB	Share
IMU Imugene Receives Vaxinia Ethics Approval in Australia
09/01/23	PRICE SENSITIVE	202.94KB	Share
IMU Letter to Shareholders
06/01/23		174.3KB	Share
IMU Notification regarding unquoted securities - IMU
22/12/22		34.22KB	Share
IMU Notification regarding unquoted securities - IMU
22/12/22		25.8KB	Share
IMU Ceasing to be a substantial holder
22/12/22		78.5KB	Share
IMU Ceasing to be a substantial holder
20/12/22		200.27KB	Share
IMU Change of Director's Interest Notice x6
20/12/22		356.36KB	Share
IMU Notification of cessation of securities - IMU
16/12/22		21.74KB	Share
IMU Notification regarding unquoted securities - IMU
16/12/22		40.1KB	Share
IMU Imugene HER-Vaxx and CF33 Platforms To Feature at ASCO
16/12/22		365.28KB	Share
IMU Imugene to Present at J.P. Morgan Healthcare Conference
12/12/22		139.32KB	Share
IMU CHECKVacc Data Presented at the 2022 SABC Symposium
09/12/22	PRICE SENSITIVE	252.41KB	Share
IMU Appendix 3H
06/12/22		222.27KB	Share
IMU Notice Under Section 708A
05/12/22		156.77KB	Share
IMU Appendix 2A
05/12/22		383.23KB	Share
IMU First Patient Dosed in VAXINIA Intravenous Cohort 2
05/12/22	PRICE SENSITIVE	250.44KB	Share
IMU Positive New HER-Vaxx HERIZON Data Presented at ESMO Asia
05/12/22	PRICE SENSITIVE	209.85KB	Share
IMU Application for quotation of securities - IMU
25/11/22		25.74KB	Share
IMU Application for quotation of securities - IMU
18/11/22		25.67KB	Share
IMU Results of Meeting
17/11/22		161.97KB	Share
IMU AGM Presentation
17/11/22		2.98MB	Share
IMU Imugene Investor Presentation
15/11/22		4.19MB	Share
IMU Imugene onCARlytics with Estrella ARTEMIS T Cells SITC
14/11/22	PRICE SENSITIVE	255.3KB	Share
IMU Application for quotation of securities - IMU
11/11/22		25.67KB	Share
IMU Dose escalates In Phase I Clinical Trial of New Oncolytic Vi
11/11/22	PRICE SENSITIVE	250.51KB	Share
IMU Imugene onCARlytics with blinatumomab SITC presentation
11/11/22	PRICE SENSITIVE	244.77KB	Share
IMU Imugene onCARlytics with Celularity CyCART-19 T Cells SITC
11/11/22	PRICE SENSITIVE	306.65KB	Share
IMU Change of Director's Interest Notice - JE & CW
09/11/22		377.77KB	Share
IMU AGM ATTENDANCE
08/11/22		162.86KB	Share
IMU ALA: Europe Patent granted for iNKT Cell Therapy Platform
07/11/22	PRICE SENSITIVE	150.42KB	Share
IMU Notice Under Section 708A
03/11/22		158.21KB	Share
IMU Application for quotation of securities - IMU
03/11/22		37.66KB	Share
IMU First patient dosed in VAXINIA intratumoral cohort 2
31/10/22	PRICE SENSITIVE	228.66KB	Share
IMU Quarterly Activities/Appendix 4C Cash Flow Report
28/10/22	PRICE SENSITIVE	608KB	Share
IMU Application for quotation of securities - IMU
27/10/22		26.55KB	Share
IMU Application for quotation of securities - IMU
21/10/22		26.54KB	Share
IMU Letter to IMUOC Optionholders
19/10/22		1022.25KB	Share
IMU Release of Shares from Escrow
19/10/22		130.31KB	Share
IMU ABL and Imugene partner to advance VAXINIA manufacturing
18/10/22		201.66KB	Share
IMU Notice of Annual General Meeting/Proxy Form
14/10/22		1.42MB	Share
IMU Application for quotation of securities - IMU
13/10/22		26.55KB	Share
IMU HERIZON study results to be featured at ESMO Asia Congress
07/10/22		188.8KB	Share
IMU onCARlytics to be showcased in three abstracts at SITC
06/10/22		211.96KB	Share
IMU Imugene appoints Paul Wright as Vice President CMC
04/10/22		188.43KB	Share
IMU Imugene appoints Dr Giovanni Selvaggi as CMO
04/10/22		189.81KB	Share
IMU ALA iNKT therapy and IMU onCARlytics - correction
27/09/22		223.26KB	Share
IMU ALA: Investor Presentation Imugene Arovella Therapies
26/09/22		4.83MB	Share
IMU Preclinical trial of ALA iNKT therapy and IMU onCARlytics
26/09/22	PRICE SENSITIVE	219.23KB	Share
IMU First patient IV dosed in VAXINIA Phase 1 clinical trial
21/09/22	PRICE SENSITIVE	189.98KB	Share
IMU Notification regarding unquoted securities - IMU
20/09/22		30.21KB	Share
IMU Notice Under Section 708A
19/09/22		152.38KB	Share
IMU Application for quotation of securities - IMU
19/09/22		26.56KB	Share
IMU OGTR grants VAXINIA DIR licence allowing trial expansion
19/09/22	PRICE SENSITIVE	212.02KB	Share
IMU Prospectus for the issue of institutional placement options
16/09/22	PRICE SENSITIVE	604.08KB	Share
IMU Proposed issue of securities - IMU
13/09/22		28.88KB	Share
IMU IMUGENE ANNOUNCES A$80 MILLION INSTITUTIONAL PLACEMENT
13/09/22	PRICE SENSITIVE	361.45KB	Share
IMU Trading Halt
12/09/22	PRICE SENSITIVE	220.02KB	Share
IMU Imugene doses first patient in nextHERIZON Phase 2 trial
08/09/22	PRICE SENSITIVE	191.8KB	Share
IMU Application for quotation of securities - IMU
07/09/22		26.5KB	Share
IMU Initial Director's Interest Notice - JD
07/09/22		161.02KB	Share
IMU Imugene appoints Dr Jakob Dupont as Non-Executive Director
07/09/22		188.56KB	Share
IMU Application for quotation of securities - IMU
02/09/22		29.16KB	Share
IMU Release of Shares from Escrow
01/09/22		130.41KB	Share
IMU Imugene Dose Escalates in Phase I Clinical Trial of VAXINIA
01/09/22	PRICE SENSITIVE	232.91KB	Share
IMU Environmental Social and Governance (ESG) Report
31/08/22		496.25KB	Share
IMU Corporate Governance Statement
31/08/22		203.19KB	Share

REFRESH

First 2 3 4 5 6

(20min delay)
Last 7.5¢		Change -0.001(1.32%)		Mkt cap ! $548.9M

Open	High	Low	Value	Volume
7.7¢	7.8¢	7.5¢	$1.261M	16.55M

Buyers (Bids)

No.	Vol.	Price($)
22	2015361	7.5¢

Sellers (Offers)

Price($)	Vol.	No.
7.6¢	590270	2

View Market Depth

No.	Vol.	Price($)
22	2015361	0.075
12	726088	0.074
14	1344158	0.073
17	1566160	0.072
25	1915656	0.071

Price($)	Vol.	No.
0.076	590270	2
0.077	691936	7
0.078	2331339	10
0.079	1384426	6
0.080	223727	5

Last trade - 16.10pm 08/05/2024 (20 minute delay)


Last 7.5¢		Change -0.001 ( 1.32 %)
Open	High	Low	Volume
7.6¢	7.8¢	7.5¢	8715272
Last updated 15.59pm 08/05/2024 ?

IMU (ASX) Chart

IMUGENE LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories